Literature DB >> 30506671

High tumour plasma cell infiltration reflects an important microenvironmental component in classic Hodgkin lymphoma linked to presence of B-symptoms.

Alex R Gholiha1, Peter Hollander2, Gustaf Hedstrom1, Christer Sundstrom2, Daniel Molin1, Karin E Smedby3, Henrik Hjalgrim3, Ingrid Glimelius1, Rose-Marie Amini2, Gunilla Enblad1.   

Abstract

Plasma cells are important prognostic actors in different malignancies. The tumour microenvironmental composition in classic Hodgkin lymphoma (cHL) is a major prognostic key element; however, clinicopathological studies regarding plasma cells in cHL are lacking. The aim of this study was to investigate CD138+ (also termed SDC1+) plasma cell and IgG4 producing (IgG4+) plasma cells infiltration in the microenvironment of cHL. Immunohistochemistry with anti-CD138 and IgG4 antibodies was performed on diagnostic tumour biopsies from 124 patients with cHL, on tissue micro array (TMA). In 120 cases, CD138+ plasma cell-infiltration was associated with the presence of B-symptoms (P = 0·028) and advanced stage, IIB-IVB (P = 0·009). In multivariate analysis, CD138+ plasma cells correlated with eosinophil infiltration (P = 0·013). The subgroup of IgG4+ plasma cells was analysed in 122 cases and only correlated to CD138+ plasma cells (P = 0·004). Patients with high proportion of tumour infiltrating CD138+ plasma cells (defined as ≥10%), had a more inferior event-free survival (P = 0·007) and overall survival (P = 0·004) than patients with a low proportion of infiltrating CD138+ plasma cells (<10%), although significance was not maintained in multivariate analysis. In summary, a high proportion of tumour-associated plasma cells in cHL reflect an important component in the microenvironment of cHL.
© 2018 British Society for Haematology and John Wiley & Sons Ltd.

Entities:  

Keywords:  CD138 plasma cells; Hodgkin's lymphoma; IgG4-producing plasma cells; Syndecan-1; tumour microenvironment

Mesh:

Substances:

Year:  2018        PMID: 30506671     DOI: 10.1111/bjh.15703

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  9 in total

1.  Revisiting IL-6 expression in the tumor microenvironment of classical Hodgkin lymphoma.

Authors:  Alex Reza Gholiha; Peter Hollander; Ingrid Glimelius; Gustaf Hedstrom; Daniel Molin; Henrik Hjalgrim; Karin E Smedby; Jamileh Hashemi; Rose-Marie Amini; Gunilla Enblad
Journal:  Blood Adv       Date:  2021-03-23

Review 2.  Targeting The Tumor Microenvironment in Lymphomas: Emerging Biological Insights and Therapeutic Strategies.

Authors:  Michael R Cook; Kieron Dunleavy
Journal:  Curr Oncol Rep       Date:  2022-04-11       Impact factor: 5.945

Review 3.  Current and Emerging Approaches to Study Microenvironmental Interactions and Drug Activity in Classical Hodgkin Lymphoma.

Authors:  Naike Casagrande; Cinzia Borghese; Donatella Aldinucci
Journal:  Cancers (Basel)       Date:  2022-05-14       Impact factor: 6.575

Review 4.  [Microenvironment in classical Hodgkin lymphoma].

Authors:  Anja Mottok
Journal:  Pathologe       Date:  2020-05       Impact factor: 1.011

Review 5.  The Hodgkin Lymphoma Immune Microenvironment: Turning Bad News into Good.

Authors:  Victoria Menéndez; José L Solórzano; Sara Fernández; Carlos Montalbán; Juan F García
Journal:  Cancers (Basel)       Date:  2022-03-07       Impact factor: 6.639

6.  Construction of an Immune-Related lncRNA Signature That Predicts Prognosis and Immune Microenvironment in Osteosarcoma Patients.

Authors:  Yi He; Haiting Zhou; Haoran Xu; Hongbo You; Hao Cheng
Journal:  Front Oncol       Date:  2022-04-14       Impact factor: 5.738

7.  Checkpoint CD47 expression in classical Hodgkin lymphoma.

Authors:  Alex Reza Gholiha; Peter Hollander; Liza Löf; Ingrid Glimelius; Gustaf Hedstrom; Daniel Molin; Henrik Hjalgrim; Karin E Smedby; Jamileh Hashemi; Rose-Marie Amini; Gunilla Enblad
Journal:  Br J Haematol       Date:  2022-03-17       Impact factor: 8.615

8.  Plasma cells in classical Hodgkin lymphoma: a new player in the microenvironment?

Authors:  Lydia Visser
Journal:  Br J Haematol       Date:  2018-11-28       Impact factor: 6.998

9.  SMAD1 promoter hypermethylation and lack of SMAD1 expression in Hodgkin lymphoma: a potential target for hypomethylating drug therapy.

Authors:  Magdalena M Gerlach; Anna Stelling-Germani; Cheuk Ting Wu; Sebastian Newrzela; Claudia Döring; Visar Vela; Anne Müller; Sylvia Hartmann; Alexandar Tzankov
Journal:  Haematologica       Date:  2021-02-01       Impact factor: 9.941

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.